Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Operating Income (2016 - 2025)

Ligand Pharmaceuticals' Operating Income history spans 16 years, with the latest figure at $13.8 million for Q4 2025.

  • For Q4 2025, Operating Income rose 243.64% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $41.0 million, up 281.38%, while the annual FY2025 figure was $41.0 million, 281.38% up from the prior year.
  • Operating Income for Q4 2025 was $13.8 million at Ligand Pharmaceuticals, down from $54.9 million in the prior quarter.
  • Across five years, Operating Income topped out at $54.9 million in Q3 2025 and bottomed at -$36.2 million in Q1 2025.
  • The 5-year median for Operating Income is $6.6 million (2021), against an average of $8.5 million.
  • The largest YoY upside for Operating Income was 1647.73% in 2025 against a maximum downside of 1312.05% in 2025.
  • A 5-year view of Operating Income shows it stood at $37.7 million in 2021, then plummeted by 67.7% to $12.2 million in 2022, then plummeted by 127.58% to -$3.4 million in 2023, then crashed by 186.99% to -$9.6 million in 2024, then soared by 243.64% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Operating Income are $13.8 million (Q4 2025), $54.9 million (Q3 2025), and $8.4 million (Q2 2025).